Paladin Labs Inc. announced that it has entered into an exclusive Canadian distribution agreement with Allergy Therapeutics plc for Pollinex(R)-R (modified ragweed tyrosine adsorbate), an allergy vaccine for the treatment of allergic rhinitis due to ragweed pollen. In addition, Paladin also received an option to acquire distribution rights to Pollinex(R)-R in Sub-Saharan Africa. Under the agreement Paladin will co-promote the product with Takeda Canada Inc. for the first eight months before taking over all selling and distribution activities.

Financial terms of the agreement were not disclosed. Pollinex(R)-R is a short-course immunotherapy vaccine of modified ragweed tyrosine adsorbate used to reduce the severity of allergic symptoms caused by exposure to ragweed. Pollinex(R)-R is administered weekly in four separate doses over the course of about one month prior to the start of the ragweed season.